In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved

In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved

.

Bibliographic Details
Main Author: Article Editorial
Format: Article
Language:Russian
Published: ABV-press 2020-01-01
Series:Onkourologiâ
Online Access:https://oncourology.abvpress.ru/oncur/article/view/1016
id doaj-ada331d0827d488990137306c5cbc183
record_format Article
spelling doaj-ada331d0827d488990137306c5cbc1832021-07-29T08:41:44ZrusABV-pressOnkourologiâ 1726-97761996-18122020-01-01154140142903In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approvedArticle Editorial.https://oncourology.abvpress.ru/oncur/article/view/1016
collection DOAJ
language Russian
format Article
sources DOAJ
author Article Editorial
spellingShingle Article Editorial
In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
Onkourologiâ
author_facet Article Editorial
author_sort Article Editorial
title In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
title_short In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
title_full In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
title_fullStr In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
title_full_unstemmed In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
title_sort in russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
publisher ABV-press
series Onkourologiâ
issn 1726-9776
1996-1812
publishDate 2020-01-01
description .
url https://oncourology.abvpress.ru/oncur/article/view/1016
work_keys_str_mv AT articleeditorial inrussiaanewindicationforpembrolizumabincombinationwithaxitinibinthefirstlinetreatmentofpatientswithadvancedrenalcellcarcinomahasbeenapproved
_version_ 1721252506182352896

Similar Items